Post Market Clinical Follow Up User Survey Report – CELOX™ Rapid

Assessment of real-world performance of CELOX™ Rapid by emergency physicians and trained emergency responders 2022

CELOX™ Rapid achieved hemostasis after the first application in 100% of cases carried out by respondents including ER physicians, medics, nurses, and other emergency personnel.

This sub-analysis from a larger CELOX™ 292 study covered 84 cases involving single or multiple wounds ranging from cutting/piercing and blunt trauma to gunshots and road traffic accidents – 90% of which were described as involving ‘moderate to severe bleeding’, 21% of which were on anticoagulation therapy.

There were no adverse events recorded.

Key Findings

100% success rate, 84/84 cases achieved hemostasis after the first application using CELOX™ Rapid – even those involving the most severe bleeding cases

No adverse events reported when using CELOX™ Rapid

All respondents across the sub-analysis rated CELOX™ Rapid ‘good’ or ‘excellent’

Conclusion

Clinical performance of CELOX™ Rapid proves to be highly successful in addressing multiple wounds in the hands of a wide range of clinical personnel needed for controlling moderate to severe bleeding. 100% of survey participants of this sub-analysis said hemostasis was achieved after the first application – even in the cases involving the most severe bleeding.

Every responder using CELOX™ Rapid said it was 100% successful, and 100% rated CELOX™ Rapid ‘good’ or ‘excellent’, with a 100% safety record.

The conclusion drawn from the sub-analysis strongly supports the efficacy of CELOX™ Rapid in real world clinical settings, especially in the high pressure and challenging conditions of the Emergency Department. CELOX™ Rapid is proven to control moderate to severe bleeding.

Read Full User Survey Report